A European research alliance tracks the onset of ataxias "Spinocerebellar ataxias" are diseases of the nervous system associated with a loss of motor coordination. A European research alliance headed ...

The FDA has issued a CRL to Biohaven regarding the NDA for troriluzole for the treatment of adults with spinocerebellar ataxia.

DENVER — Four studies presented at the American Academy of Neurology annual meeting show improvements in patients with spinocerebellar ataxia who take troriluzole. “SCAs [spinocerebellar ataxias] are, ...

OXFORD, UK / ACCESSWIRE / December 10, 2018 / IntraBio Inc., a late-stage biopharmaceutical company developing novel therapies for rare ("orphan") and common neurodegenerative diseases, announced that ...

Spinocerebellar ataxia type 7 (SCA7) is an autosomal-dominant, late-onset, slowly progressive disorder, primarily characterized by gradual loss of motor coordination, resulting from dysfunction and ...

(RTTNews) - Biohaven Ltd. (BHVN) announced that the Division of Neurology 1 within FDA's Office of Neuroscience informed the company that they have extended the PDUFA date for the troriluzole new drug ...

Q: How can I know that I am suffering from spinocerebellar ataxia? A: If you have problems with maintaining your balance while standing or walking, difficulty speaking, or eye movements, you could be ...

Biohaven is proposing troriluzole for the treatment of spinocerebellar ataxia, a group of rare, genetic diseases that lead to the progressive loss of control over movement.

Researchers have quantified the progression of the most common spinocerebellar ataxias (SCAs) over a follow-up period of up to 8 years in steps to improve sample size calculations for future ...

A new model system that can be used to develop drug therapies for genetic disorders like spinocerebellar ataxia type 6 (SCA6), has been created by researchers at the RIKEN Center for Developmental ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Back to Healio Riluzole did not improve clinical or ...

OXFORD, UK / ACCESSWIRE /December 5, 2018 / IntraBio Inc., a late-stage biopharmaceutical company developing novel therapies for rare ("orphan") and common neurodegenerative diseases, announced that ...